EP300‐Mediated MTF1‐K218 Lactylation Buffers AR‐Driven Copper Overload to Suppress Cuproptosis in Castration‐Resistant Prostate Cancer
Open Access
- 11 August 2026
- journal article
- research article
- Published by Wiley in Advanced Science
- Vol. 13 (61) , e77110
Abstract
Inducing cuproptosis for cancer therapy currently relies on supraphysiological copper or copper ionophores. Although serum copper is elevated in patients with prostate cancer, whether this is sufficient to trigger physiological cuproptosis remains unclear. Here, we show that tumor copper levels positively correlate with androgen receptor (AR) activity, and castration‐resistant prostate cancer (CRPC) with hyperactivated AR exhibits pathological copper accumulation. AR activation enhances copper uptake while simultaneously conferring tolerance to copper toxicity, creating a buffered copper state. This adaptive response is mediated by metal‐responsive transcription factor 1 (MTF1), which is transcriptionally upregulated by AR and undergoes EP300‐dependent lactylation of lysine 218, promoting copper‐induced nuclear translocation. Nuclear MTF1 activates metallothioneins (MT1E, MT1F, and MT1M) that sequester cytosolic copper and restrict mitochondrial copper accumulation. Disrupting MTF1 collapses this buffering system, enabling endogenous copper to trigger cuproptosis and suppress CRPC growth. These findings identify cuproptosis as a therapeutically exploitable vulnerability in CRPC.Keywords
Funding Information
- National Natural Science Foundation of China (82503824)
This publication has 57 references indexed in Scilit:
- A PROTAC‐Based Cuproptosis Sensitizer in Lung Cancer TherapyAdvanced Materials, 2025
- When essential metal elements become culprits—Cuproptosis in focusCancer Cell, 2025
- Ultrasound‐Triggered Nanoparticles Induce Cuproptosis for Enhancing Immunogenic Sonodynamic TherapyAdvanced Materials, 2025
- Hypoxia inducible factor-1α drives cancer resistance to cuproptosisCancer Cell, 2025
- AKT1 Phosphorylates FDX1 to Promote Cuproptosis Resistance in Triple‐Negative Breast CancerAdvanced Science, 2025
- Copper in cancer: friend or foe? Metabolism, dysregulation, and therapeutic opportunitiesCancer Communications, 2025
- Cuproplasia and cuproptosis, two sides of the coinCancer Communications, 2025
- Treatment Patterns and Survival Outcomes Among Androgen Receptor Pathway Inhibitor-Experienced Patients With Metastatic Castration-Resistant Prostate CancerClinical Genitourinary Cancer, 2024
- Enzalutamide Sensitizes Castration‐Resistant Prostate Cancer to Copper‐Mediated Cell DeathAdvanced Science, 2024
- The Molecular Signatures Database Hallmark Gene Set CollectionCell Systems, 2015